NanoVector, Inc., US
Nanovector has developed a unique plant virus nanoparticle drug delivery system which we will commercialize using a two prong strategy. First we will partner with large pharmaceutical companies to deliver oligonucleotides to the cell cytoplasm for RNAi and using our patented two-stage targeting to the cell nucleus for microRNA and gene splicing therapeutics. Secondly, we will use our nanoparticle drug delivery system as a platform to internally develop a family of targeted cancer therapeutics for the $65B/year breast and colon cancer markets. With targeted therapy only cancer cells are killed minimizing the horrendous side effects associated with the current non target free drug treatments. In addition with the Nanovector patented nuclear targeting we are the only company that can defeat the cancer cell’s defenses that leads to multi-drug resistance of current therapies and the only company that can kill the elusive cancer stem cell which is believed to cause new tumor formation. If this belief holds true we have the ability to cure certain categories of cancer. The Nanovector technology is highly sought after by large pharmaceutical companies positioning Nanovector for a huge value appreciation.
Nanotech 2008 Conference Program Abstract